{"title":"Australian Meningococcal Surveillance Programme Annual Report, 2025.","authors":"Monica Lahra, Tiffany Hogan","doi":"10.33321/cdi.2026.50.063","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.063","url":null,"abstract":"<p><p>In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). When compared to 2024, the number of IMD notifications in 2025 decreased by 13% to 118. IMD was confirmed by laboratory testing in 115/118 (97%) of 2025 IMD cases, with 66% (76/115) diagnosed by bacterial culture and 34% (39/115) by nucleic acid amplification testing. The genogroup was determined for 93% of laboratory-confirmed cases (107/115): genogroup B (MenB) accounted for 82.2% of infections (88/107); MenW and MenY for 7.5% of disease (8/107) each; MenC for 1.9% (2/107); and MenA for 0.9% (1/107). Finetyping was available for 67% of the cases for which the genogroup was determined (72/107). In MenB isolates, 28 porA types were detected: the most prevalent from amongst these were P1.7-2,4 (21%; 12/58) and P1.7,16-26 (14%; 8/58). Of the eight MenW isolates in 2025, six were finetyped and identified as porA type P1.5,2, MLST (ST) 11 and belonging to the clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. In MenY infections, four porA types were detected from the five isolates finetyped: P1.21,16; P1.5,10-1; P1.5-1,10-1; and P1.5-2,10-1, with no dominant porA type detected. One of the two MenC isolates was typed, identifying as P1.5-2,10-1 and the single MenA isolate identified as P1.5-2,10. Peaks of IMD occurred in children aged less than 5 years, in those aged 15-24 years, and in adults aged 25-44 years, accounting for 18% (21/115), 23% (26/115) and 22% (25/115) of laboratory-confirmed cases, respectively. In children aged under 5 years, 100% of IMD (21/21) was MenB; in those aged 15-24 years, 100% of IMD (25/25) was MenB; and in those aged 25-44 years, 82% of IMD (18/22) was MenB, with three MenW cases and one MenC case reported in this age group. IMD was reported in all age groups: < 5 years (18%; 21/115); 5-9 years (5%; 6/115); 10-14 years (2.6%; 3/115); 15-24 years (23%; 26/115); 25-44 years (22%; 25/115); 45-64 years (12%; 14/115); and in those aged 65 years and older (17%; 20/115). Whilst MenB predominated in all age groups, the majority of MenY IMD cases (6/8) were reported in adults aged 65 years and older, among whom it accounted for 6/18 cases (33%). All cultured IMD isolates available for antimicrobial susceptibility testing (n = 76) were tested for ceftriaxone and penicillin. Minimum inhibitory concentration (MIC) values were reported using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 8% (6/76) were defined as penicillin resistant (MIC value ≥ 0.5mg/L); 64% (49/76) had intermediate susceptibility to penicillin (MIC values 0.125 and 0.25 mg/L); and 28% (21/76) were susceptible to penicillin (MIC values ≤ 0.064 mg/L). All isolates tested were susceptible to ceftriaxone, ciprofloxacin and rifampicin.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Monitoring the incidence and causes of disease potentially transmitted by food in Australia: Annual report of the OzFoodNet network, 2020-2022.","authors":"The OzFoodNet Working Group","doi":"10.33321/cdi.2026.50.043","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.043","url":null,"abstract":"<p><p>This report summarises the incidence of enteric diseases potentially transmitted by food in Australia, and details outbreaks associated with food that occurred during 2020-2022. States and territories reported an increasing number of notifications, with a total of 48,030 notifications received in 2020; 51,294 in 2021; and 55,284 in 2022. Some foodborne diseases, particularly those commonly associated with overseas travel, observed large decreases during the reporting period compared to previous years due to measures implemented in response to the coronavirus disease 2019 (COVID-19) pandemic. The most commonly-notified conditions were campylobacteriosis (a mean of 38,403 notifications per year during 2020-2022) and salmonellosis (a mean of 10,992 notifications per year during 2020-2022). During the reporting period, a total of 285 gastrointestinal outbreaks, including 265 foodborne outbreaks, were reported. The remaining 20 outbreaks were due to environmental transmission (13 outbreaks); animal-to-person transmission (five outbreaks); and waterborne transmission (two outbreaks). Foodborne outbreaks affected 5,128 people, resulting in at least 687 hospital admissions and twelve deaths. Salmonella was the most common aetiological agent identified in foodborne outbreaks (n = 115/265; 43%), and restaurants were the most frequently reported food preparation setting (n = 130/265; 49%). Where a probable or confirmed source of the outbreak was identified, the most common causes were eggs (n = 37); seafood (n = 37); and poultry (n = 32).</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher Coulter, Justin Denholm, National Tuberculosis Advisory Committee
{"title":"National position statement: diagnosis and treatment of tuberculosis infection.","authors":"Christopher Coulter, Justin Denholm, National Tuberculosis Advisory Committee","doi":"10.33321/cdi.2026.50.067","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.067","url":null,"abstract":"<p><p>This updated National position statement replaces the National Position Statement for the Management of Latent Tuberculosis Infection (2017) and incorporates current evidence and guidance for the diagnosis and treatment of tuberculosis infection (TBI) in Australia. It provides nationally consistent recommendations on the diagnosis, risk assessment and management of TBI , including updating terminology, testing approaches, priority populations for screening and treatment, and recommended preventive treatment options.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thuy Nguyen, Nicholas Wood, Kristine Macartney, Lucy Deng
{"title":"Surveillance of adverse events following immunisation in Australia, 2024.","authors":"Thuy Nguyen, Nicholas Wood, Kristine Macartney, Lucy Deng","doi":"10.33321/cdi.2026.50.046","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.046","url":null,"abstract":"<p><p>This report summarises Australia's spontaneous surveillance data for adverse events following immunisation (AEFI) for all vaccines administered in 2024, reported to the Therapeutic Goods Administration (TGA). An adverse event(s) following immunisation is defined as any untoward medical occurrence which follows immunisation but does not necessarily have a causal relationship with use of the vaccine. Analyses of AEFI data are done continuously and also annually to detect new potential safety issues or changes to known safety issues. Overall, there were 6,232 AEFI reports for vaccines administered in 2024. This represents an annual AEFI reporting rate of 22.9 per 100,000 population and 25.7 per 100,000 vaccine doses, compared with 20.8 per 100,000 population and 24.1 per 100,000 doses in 2023. The slight increase in the AEFI reporting rates observed in 2024 was likely driven by the introduction of a new recombinant zoster vaccine (RZV, Shingrix) which replaced the live attenuated zoster vaccine (ZLV, Zostavax) on the National Immunisation Program (NIP) from November 2023, along with the expansion of the eligible population for zoster vaccination. In 2024, RZV (Shingrix) was associated with the highest number of reported AEFIs. The most frequently reported adverse events following immunisation were medication errors; hypersensitivity; gastrointestinal nonspecific symptoms; pyrexia; and injection site reaction. Among vaccines newly introduced in 2024, the most commonly reported adverse events were medication errors and nonspecific gastrointestinal symptoms for COVID-19 vaccines (Comirnaty XBB.1.5 and Spikevax XBB.1.5); hypersensitivity and pyrexia for the DTPa-HepB-IPV-Hib vaccine (Vaxelis); medication errors and exposure during pregnancy for the adjuvanted recombinant respiratory syncytial virus (RSV) pre-fusion F protein vaccine (Arexvy); and hypersensitivity and nonspecific gastrointestinal symptoms for RZV (Shingrix). Fewer deaths were reported following vaccination in 2024 (28 reports) than in 2023 (34 reports). None of the 28 reported deaths in 2024 indicated an emerging safety signal.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alicia Arnott, Thomas Tran, Marc Ramsperger, Madiyar Zhanduisenov, Changxu Zhang, Leon Caly, Ammar Aziz, Jianshu Zhang, Eloise Williams, Katherine Bond
{"title":"2025 Annual Australian Measles and Rubella Genotyping Surveillance Program Report.","authors":"Alicia Arnott, Thomas Tran, Marc Ramsperger, Madiyar Zhanduisenov, Changxu Zhang, Leon Caly, Ammar Aziz, Jianshu Zhang, Eloise Williams, Katherine Bond","doi":"10.33321/cdi.2026.50.068","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.068","url":null,"abstract":"<p><p>Molecular characterisation is a critical component of Australia's measles and rubella surveillance systems, supporting outbreak investigations, identifying sources of infection, and providing evidence for the continued maintenance of Australia's measles and rubella elimination status. This annual report summarises measles and rubella molecular epidemiology in Australia during 2025 and evaluates the utility of whole genome sequencing (WGS) for measles surveillance. In 2025, there were 181 confirmed measles cases notified in Australia, representing a 217.5% increase on the number notified in 2024. Measles virus genotypes B3 and D8 were detected, together with 21 vaccine-associated genotype A cases. Genotype B3 predominated during the first half of the year and was largely associated with importations from Vietnam, whereas genotype D8 predominated during the second half of the year and was primarily associated with importations from Indonesia. Thirty-one epidemiologically confirmed outbreaks were identified, comprising 13 genotype B3 outbreaks and 17 genotype D8 outbreaks. The discriminatory power and concordance with epidemiological data in the context of outbreak investigations was substantially greater for WGS data than for conventional N450-based genotyping. Viruses sharing the same N450-based distinct sequence identifier (DSid) differed by up to 33 single nucleotide polymorphisms (SNPs) for genotype B3 and 36 SNPs for genotype D8, whereas genomes obtained from epidemiologically linked cases differed by a maximum of four SNPs. Despite increased national case numbers in 2025, available molecular and epidemiological evidence indicated that cases were associated with importations or import-related transmission events, with no evidence of sustained endemic measles transmission. Rubella activity remained extremely low, with no rubella virus detections identified among 157 specimens tested by polymerase chain reaction (PCR) and only two notified cases nationally, neither of which had material available for genotyping. These findings support the continued absence of endemic measles and rubella transmission in Australia and highlight the value of WGS for enhancing measles surveillance and outbreak investigations.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Australian Gonococcal Surveillance Program, 1 January to 31 March 2026.","authors":"Monica Lahra, Tiffany Hogan","doi":"10.33321/cdi.2026.50.060","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.060","url":null,"abstract":"<p><p>The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 January to 31 March 2026.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C Bowers, D Pourmarzi, J Hanson, A Hempenstall, P Dugdale, C Cashman, A Fauid, G Ehlers, J Davis, D Peniyamina, L Stephens, C Taunton
{"title":"Epidemiology of malaria in the Torres Strait Islands, Australia, 2000-2025 and the public health response to three recent outbreaks.","authors":"C Bowers, D Pourmarzi, J Hanson, A Hempenstall, P Dugdale, C Cashman, A Fauid, G Ehlers, J Davis, D Peniyamina, L Stephens, C Taunton","doi":"10.33321/cdi.2026.50.065","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.065","url":null,"abstract":"<p><strong>Background: </strong>Australia was declared malaria free in 1981. However, the proximity of Australia's Torres Strait region to malaria-endemic Papua New Guinea (PNG), and the presence of the <i>Anopheles</i> mosquito across Northern Australia, means there is an ongoing risk of malaria for many Australian residents. This paper describes the epidemiology of malaria in the Torres Strait region between 2000 and 2025 and reports the public health response to three malaria outbreaks between 2023 and 2025.</p><p><strong>Methods: </strong>Case data from 1 January 2000 to 31 December 2025 were extracted from the Queensland Notifiable Conditions System to describe the epidemiology of malaria in the Torres Strait. The public health responses to each of the three recent outbreaks were reported against the Queensland Health Public Health Unit Guidelines for Malaria.</p><p><strong>Results: </strong>During the period 2000-2013, there were 171 cases of malaria reported in the Torres Strait region. Of these, 89 (52%) were positive for <i>Plasmodium falciparum</i> and 82 (48%) for <i>P. vivax</i>. Of cases during this period, 130 (76%) were imported from PNG; 13 (8%) were acquired in Australia; and 28 (16%) had an unknown place of acquisition. After a nine-year period without any confirmed malaria cases in the region, eight cases were reported across three outbreaks between 2023 and 2025. In all six of the outbreak cases in which a species could be confirmed, <i>P. vivax</i> was identified. The three outbreaks were managed effectively in partnership with local leaders, and included active case finding and vector control activities.</p><p><strong>Discussion and conclusion: </strong>The public health response successfully halted transmission of malaria during three separate outbreaks in the Torres Strait Islands. However, there is an ongoing local risk due to the high incidence of malaria in PNG and cross-border movement under the Torres Strait Treaty. Ongoing collaboration with PNG stakeholders and enhanced local surveillance are essential to minimise the future importation of malaria, and other potentially life-threatening pathogens, into mainland Australia.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jane Tuckerman, Andrew Daley, Danielle Wurzel, Ian Barr
{"title":"Nationwide survey of testing practices for respiratory viruses in Australia in the post COVID-19 pandemic era.","authors":"Jane Tuckerman, Andrew Daley, Danielle Wurzel, Ian Barr","doi":"10.33321/cdi.2026.50.008","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.008","url":null,"abstract":"<p><strong>Background: </strong>In the wake of the coronavirus disease 2019 (COVID-19) pandemic, there have been dramatic changes in the testing protocols for respiratory illness. Laboratory identification of respiratory pathogens causing clinical symptoms has become more important in the post-COVID-19 era, both for epidemiological and clinical reasons. This is particularly the case for respiratory syncytial virus (RSV) where a number of preventatives are at the point of clinical translation. The laboratory diagnosis is one of the critical elements in understanding the disease burden of respiratory pathogens and the effectiveness of preventatives. The aims of this study were to understand current laboratory testing and reporting practices across Australia.</p><p><strong>Methods: </strong>We undertook a cross-sectional survey of Australian NATA (National Association of Testing Authorities) accredited laboratories to collect data on patterns of laboratory testing, the methods used and their reporting processes. The survey asked participants to report on testing of respiratory samples for 2022 as well as current respiratory multiplex testing in 2023.</p><p><strong>Outcomes: </strong>In total, 45 out of 193 eligible laboratories (23%) completed the online survey. The majority of laboratories were from Victoria and New South Wales (31% and 27%, respectively) and most were hospital-based clinical diagnostic laboratories. Overall, 40% of responding laboratories (18/44) reported that > 80% of all tests in the molecular laboratory in 2023 were respiratory multiplex. Influenza viruses, RSV and SARS-CoV-2 were tested most frequently on respiratory multiplex PCR panels. RSV typing (RSV A or RSV B) was included in under a quarter of panels (9/43; 21%), compared to almost two-thirds for influenza typing (influenza A or influenza B: 29/44; 66%). There was considerable variability in testing platforms used, with thirty-seven laboratories using 87 different platforms (18 unique platforms). GeneXpert® (Cepheid) was the most commonly used platform; with a higher concentration of this instrument in laboratories from the eastern states (New South Wales, Queensland, Victoria). Forty percent of laboratories reported changes to respiratory testing procedures/panels in 2023 compared to the previous year. Laboratories were most likely to report results directly to the referring doctor (96-100%) followed by notifying their jurisdictional Department of Health.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Australian Rotavirus Surveillance Program: Annual Report, 2025.","authors":"Sarah Thomas, Ruth Phang, Nada Bogdanovic-Sakran, Turgut Atkepe, Julie Bines, Celeste Donato","doi":"10.33321/cdi.2026.50.061","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.061","url":null,"abstract":"<p><p>This report from the Australian Rotavirus Surveillance Program (ARSP) describes the circulating rotavirus genotypes identified in children and adults during the period 1 January to 31 December 2025. In 2025, the ARSP saw a continuation of a high burden of rotavirus disease in the Australian population. During this period, 2,419 faecal specimens were referred to the National Rotavirus Reference Centre (NRRC) for rotavirus G- and P-genotype analysis; of these samples, 2,288 were confirmed as rotavirus positive. This represents the highest number of referred samples and the highest number of positive samples recorded in a single surveillance year in the NRRC's more than 20-year history. Of the 2,288 samples confirmed rotavirus positive, 2,071 (90.5%) were identified as wildtype rotavirus; 215 (9.4%) were identified as the Rotarix vaccine-like strain; and two G1P[8] samples could not be confirmed as wildtype or vaccine-like due to inadequate sequence quality. The equine-like G3P[8] variant was the dominant genotype nationally (87.7%; n = 1,816/2,071). Other genotypes were identified at low frequencies, including wildtype G1P[8] (0.3%; n = 6/2,071), G2P[4] (2.0%; n = 42/2,071), G3P[8] (2.4%; n = 50/2,071), G8P[8] (0.5%; n = 10/2,071), G9P[4] (0.3%; n = 6/2,071), G9P[8] (2.2%; n = 46/2,071) and G12P[8] (0.3%; n = 6/2,071). Genotype distribution was consistent nationally, with equine-like G3P[8] the dominant genotype in all jurisdictions. Consistent with observations in recent years, a small number of samples with unusual genotypes were identified (3.7%; n = 77/2,071). Of these unusual genotypes, the most frequently detected was equine-like G3P[6] which accounted for 26.0% of unusual samples (n = 20/74) and 1.0% of all positive wildtype samples (n = 20/2,071). The high number of rotavirus positive samples received by the program reflected the notifications for rotavirus disease reported to the National Notifiable Diseases Surveillance Service (NNDSS). Across Australia, 9,520 notifications were recorded, which is the second highest annual total reported since rotavirus became nationally notifiable in 2018. Outbreaks were reported in the Northern Territory, Western Australia and Queensland. The ability to monitor the genotypes of rotavirus strains causing disease across ages and jurisdictions provides important data to aid in assessing the performance of the national rotavirus vaccination program and to inform public health interventions during outbreaks. The ARSP also provides important data to monitor annual variations in genotypes circulating in the population. Understanding the diversity of genotypes in circulation and the emergence of variants provides important context for any changes observed in disease epidemiology in the community. The ARSP provides diagnostic laboratories with valuable feedback on laboratory data quality by reporting incidences of wildtype, vaccine-like, and/or false positive rotavirus results.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Australian Gonococcal Surveillance Programme Annual Report, 2025.","authors":"Tiffany Hogan, Monica Lahra","doi":"10.33321/cdi.2026.50.057","DOIUrl":"https://doi.org/10.33321/cdi.2026.50.057","url":null,"abstract":"<p><p>The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in <i>Neisseria gonorrhoeae</i> (NG) for more than 45 years through the system of jurisdictional <i>Neisseria</i> reference laboratories, the National Neisseria Network (NNN). In 2025, a total of 10,204 isolates across Australia, from public and private sectors, were tested for in vitro antimicrobial susceptibility by standardised methods. In 2025, the AGSP captured antimicrobial susceptibility data for 23.9% of all gonococcal infection notifications nationally. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2025, of NG isolates tested, 0.73% (74/10,204) met the World Health Organization (WHO) criterion for decreased susceptibility (DS) to ceftriaxone, defined as a minimum inhibitory concentration (MIC) ≥ 0.125 mg/L. This proportion of isolates meeting the ceftriaxone DS criterion was greater than that reported in 2024 (0.51%), with the majority from New South Wales and Victoria. Genomic analysis indicated that 64.9% of these isolates (48/74) possessed the mosaic penA 60.001 allele, the key target associated with ceftriaxone resistance. Resistance to azithromycin was reported in 7.1% of NG isolates nationally, increasing from being proportionally stable (3.9% to 4.7%) since 2019. Of NG isolates tested, 0.20% (20/10,204) exhibited high-level resistance to azithromycin (MIC value ≥ 256 mg/L), with cases reported across Australia, predominantly in New South Wales, Victoria and non-remote Western Australia. There were ten isolates detected in 2025 that had an extensively drug-resistant (XDR) phenotype: i.e., displaying both high-level resistance to azithromycin and decreased susceptibility to ceftriaxone (MIC ≥ 0.125 mg/L). When added to the 14 XDR isolates reported during 2022-2024, this brings the total to 24 XDR NG isolates reported in Australia since 2022. Genomic analyses of the ten XDR isolates reported in 2025 indicated all harboured the mosaic penA 60.001 allele, with several differing sequence types (ST) identified. By contrast, during 2022 and 2024, XDR NG sequence types were limited to ST-16406, consistent with reports from Europe and England. Travel information, where available, indicates infections in 2025 were associated with travel to Southeast Asia but also arose where no travel was involved. In 2025, penicillin resistance was found in 23.4% of gonococcal isolates, and ciprofloxacin resistance in 59.3% of isolates where tested, although there was variation by jurisdiction particularly in remote settings, where acquisition of cultures for antimicrobial susceptibility testing is low. Tetracycline resistance has been included in surveillance in the AGSP in recent years, coincident with increasing use of doxycycline post-exposure prophylaxis for syphilis and chlamydia. Nationally 36.2% of NG isolates in 2025 were tetracyclin","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"50 ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}